Regarding the third criterion, MYC-dependent tumor cell inhibition, MYCMI-6, MYCMI-11 and MYCMI-14 inhibited growth of neuroblastoma cells with MYCN-amplification to a significantly larger extent than MYCN-non-amplified cell lines, which correlated with the much higher expression of MYCN in the MYCN-amplified cell lines than of MYC in the non-amplified cell lines as determined by western blot analysis using pan-MYC antibodies (Fig. 5). The gene discussed is MYCN; the disease is neoplasm.